undamentalytics Newsletter
Sign in

Regeneron Pharmaceuticals (REGN) stock

Add to watchlist

Add holding +

NASDAQ: REGN Nasdaq Biotechnology Next results ~January 28, 2027

B+ Fundamentals grade

Regeneron Pharmaceuticals is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$980

Cash-flow model

Base case. Range ~$760–$1300 across our lower- and higher-growth cases (8.7%–18.7% a year).

Price vs value

Modestly undervalued

The price is inside our value range, 1% below our base value.

Price used: $971.80, November 3, 2026

Regeneron Pharmaceuticals valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Regeneron Pharmaceuticals files

10-Q filed October 30: Regeneron Pharmaceuticals

Model value +34.3%

Revenue for the twelve months to September 2026 was $16.9bn, up 18.6% on a year earlier, faster than the 9.3% growth a quarter earlier. Free-cash-flow margin fell to 22.6% from 29.6% a year earlier. Operating margin widened to 28.8% from 25.9%. The diluted share count is down 3.2% on a year earlier, which lifts each remaining share. Our model value rises from $732 to $983 a share, against a share price of $928. The rating stays Hold. At that price, our model says the market is pricing in about 11.2% a year of cash-flow growth for five years, faster than the 1.0% a year revenue growth it has delivered.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (2)

10-Q filed July 30: Regeneron Pharmaceuticals

Regeneron's revenue reached $16.9bn in the twelve months to June 2026, up 18.6% on a year earlier and a marked acceleration from the 9.3% growth seen a quarter earlier. Profitability told a mixed story: the operating margin widened to 28.8% from 25.9%, while the free-cash-flow margin slipped to 22.6% from 29.6%. A 3.2% reduction in the diluted share count has given remaining holders a larger claim on earnings. Taken together, these shifts pushed the fundamentals grade up from C+ to B+. Our model value is barely changed at $732 a share, well below the $815 share price. At that level, the market appears to be pricing in cash-flow growth of around 10.9% a year for five years, far ahead of the 1.0% annual revenue growth actually delivered. The rating remains Hold.

10-Q on SEC EDGAR

Where Regeneron Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $15.5bn, up 9.3% on a year earlier, faster than 5.9% a quarter earlier. Free-cash-flow margin fell to 24.2% from 27.1% a year earlier. Operating margin narrowed to 24.7% from 27.0%. The diluted share count is down 4.8% on a year earlier, which lifts each remaining share. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 7 of our 7 financial-health checks. Our cash-flow model value is $644 a share, against a share price of $794. At that price, our model says the market is pricing in about 12.2% a year of cash-flow growth for five years, faster than the -0.7% a year revenue growth it has delivered.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 28, 2027 (estimated)

Regeneron Pharmaceuticals's trailing-twelve-month revenue grew 18.6% year on year, with a free-cash-flow margin of 22.6%. Where it stands out: change in share count of -3.2% ranks 10 of 156 biotechnology companies we cover. Where it lags: days sales outstanding of 164 days ranks 90 of 100 biotechnology companies we cover.

Our discounted-cash-flow model values the business at ~$980 per share in the base case (~$760–$1300 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Revenue growth accelerating: TTM revenue growth rose to 18.6% (+9.3pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 18.6% over the last 12 months, against a median of 12.6% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 9.3 points higher than a quarter earlier.
  • High operating margin. 28.8% of revenue is left as operating profit, against a median of -189.4% for biotechnology companies we cover.
  • Strong cash generation. 22.6% of revenue turned into free cash flow, against a median of -145.4% for biotechnology companies we cover.
  • Shrinking share count. Diluted shares fell 3.2% in a year, so each share owns more of the business.

Things to watch

  • Insiders selling. 7 insiders sold $12M of stock over the past 365 days and none bought (98% under pre-set trading plans).
  • Weak cash conversion. Free cash flow was 79% of net income over the last 12 months.
  • Below peers: days sales outstanding. Days sales outstanding of 164 days ranks 90 of 100 biotechnology companies we cover (median 75 days).

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
$20.07 against an average estimate of $16.25: beat by 23.5%
Revenue
$5.12bn, up 36.3% on a year earlier
Share reaction
+17.4% in the first session after the results on October 30, 2026, against -2.2% for the S&P 500
Guidance given
GAAP R&D $6.5bn to $6.64bn (full year 2026); non-GAAP R&D $5.95bn to $6.05bn (full year 2026)
Next report
January 28, 2027; average EPS estimate $20.50

Regeneron Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+1.1%
  • 1 week+19.1%
  • 1 month+32.2%
  • This year+25.0%
  • 1 year+52.1%
  • 5 years+51.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$16.9B
Operating margin
28.8%
Net margin
28.5%
EPS (TTM, diluted)
$45.16

Growth

Revenue growth
+18.6%
Change in growth rate
+9.3 pts
Share count change
−3.2%

Cash

Free cash flow (TTM)
$3.8B
FCF margin
22.6%
Stock pay % of revenue
5.9%

Earnings

Last results
October 30, 2026

News & updates

Updated November 1, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Our research
  2. Our research
  3. Results
  4. Insider trade
  5. Results
  6. Leadership
  7. Results
  8. Guidance
  9. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Regeneron Pharmaceuticals valuation models and calculator

What the price is pricing in

The share price implies about 12.1% a year of cash-flow growth for five years.That is faster than the 1.0% a year revenue growth Regeneron Pharmaceuticals has delivered.

  • Priced in12.1%
  • Last 12 months18.6%
  • 3 years a year8.9%
  • 5 years a year1.0%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($971.02, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$980
Price used
$971.02close November 3, 2026
Implied change
▲ +1%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Regeneron Pharmaceuticals's free cash flow after stock-based pay with after-tax interest added back ($3.2B, FY2026 Q3 TTM), growing 10.1% and 11% in the next two years (forecasts, guidance and its record), then back to 13.7% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$760–~$1300 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Regeneron Pharmaceuticals's free cash flow after stock-based pay ( $3.2B, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Regeneron Pharmaceuticals as an operating company, with every model that fits that kind of business. Cost of equity 8.6%: the 10-year Treasury yield (4.9%) plus a beta of 0.8 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$980 ~$760–$1300 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$630 ~$590–$1200 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$1100 ~$730–$1600 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$880 ~$750–$1100 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$910 ~$630–$1100 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Regeneron Pharmaceuticals with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −23%
  • Revenue growth 5 points higher ▲ +29%
  • Free-cash-flow margin 1 point lower ▼ −4%
  • Last year's free-cash-flow margin change, if it persists ▼ −23%
  • Discount rate 1 point higher ▼ −15%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $512$670$880$1156$1517$1983
8.5% $408$523$674$872$1129$1459
10% $345$434$550$702$897$1148

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$537.79$363.66$372.45$370.01$371.97$478.59$625.62$714.75$870.08$705.67$768.89$961.26
Market value$62.0bn$42.3bn$43.2bn$42.5bn$42.6bn$55.1bn$70.2bn$81.1bn$98.9bn$81.2bn$83.5bn$102.5bn
+ Net debt (− = net cash)−$809m−$535m−$813m−$1.5bn−$1.6bn−$215m−$906m−$1.1bn−$747m−$504m−$1.1bn−$1.7bn
Enterprise value$61.2bn$41.8bn$42.4bn$41.0bn$41.0bn$54.9bn$69.3bn$80.0bn$98.2bn$80.7bn$82.4bn$100.9bn
Multiples
Price / sales 15.1x8.7x7.4x8.3x6.5x6.5x4.4x6.7x7.5x5.7x5.8x6.1x
Price / earnings 97.4x47.2x36.0x17.4x20.1x15.7x8.7x18.7x25.0x18.4x18.5x21.3x
Price / free cash flow 94.9x43.4x41.7x23.4x21.3x27.5x10.8x18.3x25.5x22.2x20.5x26.8x
EV / EBITDA 46.1x29.1x19.0x15.3x16.9x14.4x7.5x15.7x22.0x18.0x20.0x18.8x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

86 /100

Strong moat

How hard Regeneron Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Net income has been a median 15.0% of total assets over 10 years.

  • Durability 20 / 20

    Operating margin has been a median 34.1%; its worst year was 25.9%.

  • Cash conversion 20 / 20

    Free cash flow was positive in 10 of 10 years, at a median 27.6% of revenue.

  • Discipline 12 / 20

    The diluted share count fell 4.9% over five years; stock-based pay has been a median 6.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (90 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: January 28, 2027, before the open. Analysts expect revenue of $5.3bn and EPS of $20.50 (range $14.66 to $25.95) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $59.10 +33% $17.6bn +23%
Next $52.07 +8% $18.6bn +6%

Next year's EPS estimate has moved +9.3% in 90 days, across 10 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +28.8% on 90 days ago. In the last 30 days, 9 analysts raised Regeneron Pharmaceuticals's forecast and 1 cut it.

Consensus EPS forecast Regeneron Pharmaceuticals, last 90 days
$45.00 $50.00 $55.00 $60.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $45.87 Current fiscal year, 60 days ago: $53.55 Current fiscal year, 30 days ago: $54.10 Current fiscal year, 7 days ago: $58.55 Current fiscal year, Now: $59.10 $59.10 Next fiscal year, 90 days ago: $47.63 Next fiscal year, 60 days ago: $50.38 Next fiscal year, 30 days ago: $50.63 Next fiscal year, 7 days ago: $51.06 Next fiscal year, Now: $52.07 $52.07

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $45.87$47.63
60 days ago $53.55$50.38
30 days ago $54.10$50.63
7 days ago $58.55$51.06
Now $59.10$52.07

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $16.25 $20.07 +23.5%
Jun 2026 $10.21 $14.29 +40.0%
Mar 2026 $8.90 $9.47 +6.4%
Dec 2025 $10.75 $11.44 +6.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, July 30, 2026
  • GAAP gross margin on net product sales full year 2026 78% to 79% GAAP Raised
    “GAAP gross margin on net product sales 77%-78% 78%-79%” source
  • Non-GAAP gross margin on net product sales full year 2026 84% to 85% Non-GAAP Raised
    “Non-GAAP gross margin on net product sales (a) 83%-84% 84%-85%” source
  • GAAP R&D full year 2026 $6.5bn to $6.635bn GAAP Narrowed
    “GAAP R&D $6.450-$6.680 billion $6.500-$6.635 billion” source
  • Non-GAAP R&D full year 2026 $5.95bn to $6.05bn Non-GAAP Narrowed
    “Non-GAAP R&D (a) $5.900-$6.100 billion $5.950-$6.050 billion” source
  • GAAP SG&A full year 2026 $2.83bn to $2.96bn GAAP Lowered
    “GAAP SG&A $2.860-$3.040 billion $2.830-$2.960 billion” source
  • Non-GAAP SG&A full year 2026 $2.5bn to $2.6bn Non-GAAP Narrowed
    “Non-GAAP SG&A (a) $2.500-$2.650 billion $2.500-$2.600 billion” source
Show 3 more items
  • Capital expenditures full year 2026 $1.03bn to $1.1bn Lowered
    “Capital expenditures $1.100-$1.200 billion $1.030-$1.100 billion” source
  • GAAP effective tax rate full year 2026 13% to 14% GAAP Narrowed
    “GAAP effective tax rate 12%-14% 13%-14%” source
  • Non-GAAP effective tax rate full year 2026 14% to 15% Non-GAAP Narrowed
    “Non-GAAP effective tax rate (a) 13%-15% 14%-15%” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Regeneron Pharmaceuticals's revenue by +10.1% next year and +11.0% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+8.6%, weight 70%) and the company's own record (+13.7%, weight 30%) . How the weights are set.

Analyst recommendations

28 analysts, Oct 2026
Buy1968%
Hold829%
Sell14%

Monthly trend

  1. Oct 2026415828
  2. Sep 2026413927
  3. Aug 2026414928
  4. Jul 20264141028

Counts of recommendations published by analysts covering Regeneron Pharmaceuticals, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.2%
of tradable shares
Days to cover
2.78
at average volume
Short interest, 1 month
−15%
to October 15, 2026
Held by institutions
93%
of shares
Held by insiders
2.1%
of shares
Employees
15,410
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +48.2%

$648.47 on October 31, 2025 to $961.26

ThenNowEffect
Revenue (last 12 months) $14.2bn $15.5bn +9.3%
Net margin 31.4% 27.9% −11.2%
P/E multiple 16.4x 23.8x +45.4%
Share count 112m 107m +5.0%

Biggest factor: p/e multiple.

Last 3 years +18.8%

$809.26 on November 3, 2023 to $961.26

ThenNowEffect
Revenue (last 12 months) $12.7bn $15.5bn +22.6%
Net margin 33.9% 27.9% −17.9%
P/E multiple 21.4x 23.8x +11.1%
Share count 114m 107m +6.2%

Biggest factor: revenue.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
REGN+31%+14%+22%−19%+9%+25%
Industry peers (median)−36%−57%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
REGN67%50%58%50%50%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
REGN−20%−26%−17%−42%−35%−26%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 60% from August 27, 2024 to June 5, 2025. Getting back needed a 148% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$599.96 – $961.26
From 52-week high
0.0%
vs 50-day average
+20.8%
vs 200-day average
+30.4%
Volatility (1 year)
34%
Beta vs S&P 500
0.31

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±5.3%
After a week
6 up, 5 down
typical move ±5.2%
After a month
6 up, 4 down
typical move ±10.3%
Results releasedNext dayS&P 500 next day5 days21 days
October 30, 2026 +17.4% −2.2% — —
October 6, 2026 +2.2% +0.3% +3.7% —
July 30, 2026 +9.7% +2.4% +11.0% +14.3%
July 6, 2026 +3.4% +0.4% +1.3% +16.3%
April 29, 2026 −3.4% +1.0% −1.5% −15.9%
April 8, 2026 +1.0% +3.1% −0.8% −6.7%
January 30, 2026 +0.7% +0.2% +4.8% +2.4%
January 12, 2026 −4.7% 0.0% −7.9% −2.2%
October 28, 2025 +11.5% +0.3% +7.3% +34.2%
October 6, 2025 −2.8% 0.0% −7.0% +4.7%
August 1, 2025 +4.8% −0.1% +3.2% +6.1%
April 29, 2025 −2.0% +0.7% −8.6% −0.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Regeneron Pharmaceuticals’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Results just out

Results came out in the last few days. Option prices are still adjusting, so we do not judge them yet.

  • Implied is 3.90× the last 60 days’ realised volatility .
  • Puts are priced 226 points richer than calls (25-delta): the market is paying up for downside protection, which favours selling puts over calls.
  • Why: results came out in the last few days, so option prices are still adjusting.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

REGN Regeneron Pharmaceuticals Grade B+ $964.92

Sell the $950 put expiring December 18, 2026 (46 days) for $340 a share — $34,000 per contract.

Previous session · Bid $340, ask $350, quoted Mon 2 Nov, 17:34 New York time with REGN at $964.92. Option prices move with the shares: check the live chain at your broker before trading.

  • If REGN ends above $950: you keep the $34,000 — 35.8% on the $95,000 set aside, or 284.0% a year at that pace.
  • If it ends below $950: you buy 100 shares at an effective $610, 37% below today's price and 38% below our value of ~$980.
$34.0k $0 −$12.2k Break-even $610 Price $964.92 Our value $980
Profit or loss per contract at expiry, by share price.
Premium
$34,000
Annualised
284.0%
Break-even
$610
Max gain
$34,000
Chance of buying
~31%
REGN Regeneron Pharmaceuticals Grade B+ $964.92

Own 100 shares, sell the $1,000 call expiring December 18, 2026 (46 days) for $31.80 a share — $3,180 per contract.

Previous session · Bid $31.80, ask $39.20, quoted Mon 2 Nov, 17:34 New York time with REGN at $964.92. Option prices move with the shares: check the live chain at your broker before trading.

  • If REGN ends below $1,000: you keep your shares and the $3,180 — 3.3% extra on the position, 26.2% a year at that pace.
  • If it ends above $1,000: your shares are sold at $1,000, a total return of 6.9% including the premium — at or above our value of ~$980.
$6.7k $0 −$18.7k Break-even $933.12 Price $964.92 Our value $980
Profit or loss per contract at expiry, by share price (including the shares bought at today's price).
Premium
$3,180
Annualised
26.2%
Break-even
$933.12
Max gain
$6,688.5
Chance of selling
~44%

Collar

Not offered: the shares trade below our fair value: a collar caps upside the model expects.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Regeneron Pharmaceuticals in five measures

Fundamentals grade B+
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Regeneron Pharmaceuticals
$13B $14B $15B $16B $17B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $13.1B Revenue (TTM), FY24 Q1: $13.1B Revenue (TTM), FY24 Q2: $13.5B Revenue (TTM), FY24 Q3: $13.8B Revenue (TTM), FY24 Q4: $14.2B Revenue (TTM), FY25 Q1: $14.1B Revenue (TTM), FY25 Q2: $14.2B Revenue (TTM), FY25 Q3: $14.2B Revenue (TTM), FY25 Q4: $14.3B Revenue (TTM), FY26 Q1: $14.9B Revenue (TTM), FY26 Q2: $15.5B Revenue (TTM), FY26 Q3: $16.9B $16.9B

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $13.1B
FY24 Q1 $13.1B
FY24 Q2 $13.5B
FY24 Q3 $13.8B
FY24 Q4 $14.2B
FY25 Q1 $14.1B
FY25 Q2 $14.2B
FY25 Q3 $14.2B
FY25 Q4 $14.3B
FY26 Q1 $14.9B
FY26 Q2 $15.5B
FY26 Q3 $16.9B
Revenue growth, TTM YoY Regeneron Pharmaceuticals
0% 5% 10% 15% 20% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 7.8% Revenue growth, TTM YoY, FY24 Q1: 5.9% Revenue growth, TTM YoY, FY24 Q2: 6.5% Revenue growth, TTM YoY, FY24 Q3: 5.7% Revenue growth, TTM YoY, FY24 Q4: 8.3% Revenue growth, TTM YoY, FY25 Q1: 7.5% Revenue growth, TTM YoY, FY25 Q2: 5.4% Revenue growth, TTM YoY, FY25 Q3: 2.9% Revenue growth, TTM YoY, FY25 Q4: 1.0% Revenue growth, TTM YoY, FY26 Q1: 5.9% Revenue growth, TTM YoY, FY26 Q2: 9.3% Revenue growth, TTM YoY, FY26 Q3: 18.6% 18.6%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 7.8%
FY24 Q1 5.9%
FY24 Q2 6.5%
FY24 Q3 5.7%
FY24 Q4 8.3%
FY25 Q1 7.5%
FY25 Q2 5.4%
FY25 Q3 2.9%
FY25 Q4 1.0%
FY26 Q1 5.9%
FY26 Q2 9.3%
FY26 Q3 18.6%
Operating margin (TTM) Regeneron Pharmaceuticals
24% 26% 28% 30% 32% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 30.9% Operating margin (TTM), FY24 Q1: 29.4% Operating margin (TTM), FY24 Q2: 28.9% Operating margin (TTM), FY24 Q3: 28.7% Operating margin (TTM), FY24 Q4: 28.1% Operating margin (TTM), FY25 Q1: 27.2% Operating margin (TTM), FY25 Q2: 27.0% Operating margin (TTM), FY25 Q3: 25.9% Operating margin (TTM), FY25 Q4: 24.9% Operating margin (TTM), FY26 Q1: 24.3% Operating margin (TTM), FY26 Q2: 24.7% Operating margin (TTM), FY26 Q3: 28.8% 28.8%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 30.9%
FY24 Q1 29.4%
FY24 Q2 28.9%
FY24 Q3 28.7%
FY24 Q4 28.1%
FY25 Q1 27.2%
FY25 Q2 27.0%
FY25 Q3 25.9%
FY25 Q4 24.9%
FY26 Q1 24.3%
FY26 Q2 24.7%
FY26 Q3 28.8%
FCF margin (TTM) Regeneron Pharmaceuticals
20% 25% 30% 35% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 29.5% FCF margin (TTM), FY24 Q1: 31.0% FCF margin (TTM), FY24 Q2: 24.7% FCF margin (TTM), FY24 Q3: 24.8% FCF margin (TTM), FY24 Q4: 25.8% FCF margin (TTM), FY25 Q1: 22.0% FCF margin (TTM), FY25 Q2: 27.1% FCF margin (TTM), FY25 Q3: 29.6% FCF margin (TTM), FY25 Q4: 28.4% FCF margin (TTM), FY26 Q1: 27.6% FCF margin (TTM), FY26 Q2: 24.2% FCF margin (TTM), FY26 Q3: 22.6% 22.6%

Source: SEC EDGAR filings. Retrieved October 30, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 29.5%
FY24 Q1 31.0%
FY24 Q2 24.7%
FY24 Q3 24.8%
FY24 Q4 25.8%
FY25 Q1 22.0%
FY25 Q2 27.1%
FY25 Q3 29.6%
FY25 Q4 28.4%
FY26 Q1 27.6%
FY26 Q2 24.2%
FY26 Q3 22.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Regeneron Pharmaceuticals took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $14.3B
  2. Other income $1.7B · 11.5%
  3. Research and development $5.9B · 40.8%
  4. Selling, general and admin $2.7B · 18.8%
  5. Other operating costs $2.2B · 15.4%
  6. Operating income $3.6B · 24.9%
  7. Income tax $726M · 5.1%
  8. Net income $4.5B · 31.4%

Shares of revenue. Source: Regeneron Pharmaceuticals's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained. Other income is income outside operations, such as investment gains.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 0.4 0.5 0.4 1.4 2.1 2.8 4.1 4.9 5.9 5.1 6.6 8.5 16.1 12.2 13.1 14.2 14.3 16.9
Gross profit — — — — — — — — — 4.9 6.2 — — — — — — —
EBITDA −0.1 −0.1 −0.2 0.5 0.8 0.9 1.3 1.4 2.2 2.7 2.4 3.8 9.2 5.1 4.5 4.5 4.1 5.4
Operating income −0.1 −0.1 −0.2 0.5 0.7 0.8 1.3 1.3 2.1 2.5 2.2 3.6 8.9 4.7 4.0 4.0 3.6 4.9
Net income −0.1 −0.1 −0.2 0.8 0.4 0.3 0.6 0.9 1.2 2.4 2.1 3.5 8.1 4.3 4.0 4.4 4.5 4.8
Diluted EPS −$0.85 −$1.26 −$2.45 $6.75 $3.72 $2.98 $5.52 $7.70 $10.34 $21.29 $18.46 $30.52 $71.97 $38.22 $34.77 $38.34 $41.48 $45.16
Growth (year on year)
Revenue +59.1% +21.0% −2.9% +209.2% +52.7% +34.0% +45.5% +18.4% +20.8% −12.4% +27.4% +29.6% +89.1% −24.3% +7.8% +8.3% +1.0% +18.6%
EBITDA — — — — +58.5% +11.8% +51.4% +8.2% +55.0% +20.6% −9.8% +57.5% +142.2% −45.0% −12.1% +0.1% −7.9% +27.6%
Operating income — — — — +62.3% +10.9% +51.9% +6.3% +56.3% +21.9% −12.8% +61.9% +150.1% −47.0% −14.6% −1.4% −10.3% +31.9%
Net income — — — — −44.9% −18.3% +88.1% +40.8% +33.8% +104.0% −13.4% +66.0% +129.9% −46.3% −8.9% +11.6% +2.1% +5.2%
Diluted EPS — — — — −44.9% −19.9% +85.2% +39.5% +34.3% +105.9% −13.3% +65.3% +135.8% −46.9% −9.0% +10.3% +8.2% +8.7%
Margins
Gross margin — — — — — — — — — 95.4% 93.9% — — — — — — —
EBITDA margin −15.8% −16.9% −39.0% 35.9% 37.3% 31.1% 32.3% 29.5% 37.9% 52.1% 36.9% 44.9% 57.4% 41.7% 34.1% 31.5% 28.7% 31.8%
Operating margin −19.5% −21.2% −46.0% 33.2% 35.3% 29.2% 30.5% 27.4% 35.4% 49.3% 33.7% 42.1% 55.7% 38.9% 30.9% 28.1% 24.9% 28.8%
Net margin −17.9% −22.8% −49.7% 54.4% 19.7% 12.0% 15.5% 18.4% 20.4% 47.5% 32.3% 41.3% 50.2% 35.6% 30.1% 31.1% 31.4% 28.5%
Free-cash-flow margin −44.1% −0.1% −44.6% −9.0% 20.5% 14.9% 15.9% 20.0% 17.6% 35.2% 30.5% 23.6% 40.6% 36.3% 29.5% 25.8% 28.4% 22.6%
Cash flow
Cash from operations −0.1 0.1 −0.1 −0.1 0.6 0.8 1.3 1.5 1.3 2.2 2.4 2.6 7.1 5.0 4.6 4.4 5.0 4.8
Capital spending 0.1 0.1 0.1 0.0 0.2 0.3 0.7 0.5 0.3 0.4 0.4 0.6 0.6 0.6 0.7 0.8 0.9 1.0
Free cash flow −0.2 −0.0 −0.2 −0.1 0.4 0.4 0.7 1.0 1.0 1.8 2.0 2.0 6.5 4.4 3.9 3.7 4.1 3.8
Stock-based pay 0.0 0.0 0.1 0.1 0.2 0.3 0.5 0.6 0.5 0.4 0.5 0.4 0.6 0.7 0.9 1.0 1.0 1.0
Free cash flow after stock pay −0.2 −0.0 −0.3 −0.2 0.2 0.1 0.2 0.4 0.5 1.4 1.5 1.6 5.9 3.7 3.0 2.7 3.1 2.8
Balance sheet
Cash 0.2 0.1 0.5 0.2 0.5 0.6 0.8 0.5 0.8 1.5 1.6 2.2 2.9 3.1 2.7 2.5 3.1 3.7
Total debt 0.0 0.0 0.3 0.3 0.3 0.2 0.0 0.0 0.0 0.0 0.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
Net debt (negative = net cash) −0.2 −0.1 −0.2 0.1 −0.2 −0.5 −0.8 −0.5 −0.8 −1.5 −1.6 −0.2 −0.9 −1.1 −0.7 −0.5 −1.1 −1.7
Diluted shares — 83m 91m 115m 111m 113m 115m 116m 116m 115m 115m 115m 112m 114m 114m 115m 109m 107m
Returned to shareholders
Dividends — — — — — — — — — — — — — — 0.0 0.0 0.4 0.4
Buybacks — — — — — — — 0.0 0.0 0.0 0.3 5.8 1.6 2.1 2.2 2.6 3.4 3.0
Total returned — — — — — — — 0.0 0.0 0.0 0.3 5.8 1.6 2.1 2.2 2.6 3.8 3.4

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

7 of 7 checks passed · September 30, 2026
What it owns · $44.4bn
Short-term assets $20.8bnLonger-term assets $23.6bn
What it owes, and who funded it · $44.4bn
Short-term liabilities $6.2bnLonger-term liabilities $4.7bnShareholders' equity $33.5bn
  • Short-term assets cover short-term liabilities $20.8bn of assets due within a year against $6.2bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $20.8bn short-term assets against $4.7bn of longer-dated liabilities.
  • More cash than debt $3.7bn of cash against $2.0bn of debt.
  • Debt below 40% of shareholders' equity Debt is 6% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 10% to 6% over five years.
  • A year's operating cash flow covers at least 20% of debt $4.8bn of operating cash flow against $2.0bn of debt.
  • Operating profit covers interest at least five times over Operating income of $4.9bn against $47m of interest.

From Regeneron Pharmaceuticals's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$3B
Dividends (TTM)
$383M
Returned to shareholders
89%
of free cash flow
Buybacks, last 3 fiscal years
$8.3B
Diluted share count
−3.2%
year over year
Total shareholder yield
3.4%
dividends 0.4% + buybacks 3.0% of market value
Dividend payout ratio
8%
of net income paid out
R&D spending
39.0%
of revenue
Sales & admin spending
16.4%
of revenue
Days sales outstanding
164 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated REGN VRTX BIIB GILD AMGN INCY Median
Revenue, last 12 months $16.9bn $12.6bn $10.3bn $31.0bn $38.1bn $6.0bn $56m
Revenue growth, last 12 months 18.6% 10.2% 2.3% 6.5% 9.1% 24.9% 12.6%
Revenue growth, 3-year average 8.9% 9.8% 1.0% 4.2% 12.7% 18.5% 13.7%
Revenue growth, latest quarter 36.3% 12.5% 10.6% 6.8% 9.5% 14.0% 10.2%
Gross margin — 86.0% 74.0% 79.9% 69.5% 92.7% 82.9%
Operating margin 28.8% 38.0% 22.9% −7.6% 30.0% 10.4% −189.4%
Operating margin, 3-year average 27.8% 23.0% 34.4% 10.4% 24.5% 13.3% −363.5%
Net margin 28.5% 35.0% 3.4% −12.5% 23.0% 6.7% −169.8%
Cash from operations / revenue 28.7% 34.1% 21.8% 46.7% 32.8% 12.4% −168.0%
Free-cash-flow margin 22.6% 30.2% 20.1% 44.5% 26.7% 10.8% −162.4%
Free-cash-flow margin, 3-year average 25.7% 16.5% 21.1% 36.4% 24.9% 11.7% −310.0%
Stock pay / revenue 5.9% 5.5% 3.0% 2.9% 1.3% 4.4% 20.0%
Change in share count −3.2% −0.6% 1.2% −0.7% 0.2% 2.9% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 18.6% 12.6% 80 of 172
Change in growth rate Growth +9.3pp -0.1pp 46 of 172
Operating margin Profitability 28.8% -189.4% 16 of 175
Net margin Profitability 28.5% -157.3% 20 of 180
Free-cash-flow margin Cash generation 22.6% -145.4% 20 of 176
Stock pay as % of revenue Cash generation 5.9% 19.2% 39 of 179
Long-term debt as % of assets Balance sheet 4.5% 20.6% 20 of 78
Change in share count Balance sheet -3.2% 7.9% 10 of 156
Days sales outstanding Balance sheet 164 days 75 days 90 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Collaboration Revenue $7.3B ▲ 21.0%
Products $6.3B ▼ 17.3%
LIBTAYO Net Product Sales $1.5B ▲ 19.3%
Other $703M ▲ 36.4%
Other Products $10.1M —

These categories overlap or exclude eliminations, so shares aren't shown.

From Regeneron Pharmaceuticals's 10-K filed February 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$57.2B
Institutions reporting
1,323
Shares held vs prior quarter
▲ 1.2%
Positions opened / closed
106 / 165

Top buyers and sellers, Q2 2026: 589 institutions bought and 699 sold ; the biggest buyer was Vanguard Portfolio Management LLC (+1.5M shares) and the biggest seller FMR LLC (−686K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $5.7B 9.1M 9.9% ▲ 1.9%
Vanguard Capital Management LLC $4.1B 6.6M 7.2% ▼ 0.4%
Dodge & Cox $3B 4.9M 5.3% ▲ 9.3%
State Street Corp $3B 4.8M 5.3% ▲ 3.6%
Invesco Ltd. $2.5B 3.9M 4.3% ▲ 0.9%
Jpmorgan Chase & Co $2.4B 3.8M 4.2% ▼ 12.5%
Vanguard Portfolio Management LLC $2B 3.2M 3.5% ▲ 84.5%
Franklin Resources Inc $1.7B 2.8M 3.0% ▲ 1.8%
Geode Capital Management, LLC $1.6B 2.6M 2.9% ▲ 0.7%
Nuveen, LLC $1.3B 2.0M 2.2% ▼ 2.2%
Loomis Sayles & Co L P $1.2B 1.9M 2.0% ▼ 2.8%
Price T Rowe Associates Inc $954M 1.5M 1.7% ▼ 29.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Regeneron Pharmaceuticals's complete shareholder register. Values are as reported by the filers ; 4 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $11.9M 105 trades by 7 insiders · 98% under pre-set plans
Net ▼ $11.9M net selling
Insider Date Trade Shares Price Value
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 50 $781.47 $39,074
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 463 $780.63 $361,432
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 380 $779.59 $296,244
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 454 $778.64 $353,503
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 38 $777.76 $29,555
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 66 $776.31 $51,236
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 376 $775.46 $291,573
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 121 $774.48 $93,712
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 224 $773.40 $173,242
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 211 $772.56 $163,010
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 283 $771.56 $218,351
Murphy Andrew J Co-Chief Scientific Officer October 14, 2026 Sell pre-set plan 12 $770.20 $9,242

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 71 trades and filings

In the last 12 months, 2 members of Congress disclosed 2 purchases and 1 sale of Regeneron Pharmaceuticals shares.

  • Gilbert Ray Cisneros, Jr.(D-CA 31):Sale (full), $1,001 - $15,000, traded May 15, 2026, filed June 8, 2026
  • Julia Letlow(R-LA 5):Purchase, $1,001 - $15,000, traded February 12, 2026, filed March 12, 2026
  • Gilbert Ray Cisneros, Jr.(D-CA 31):Purchase, $1,001 - $15,000, traded November 18, 2025, filed December 15, 2025

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

  • October 30, 2026
  • October 6, 2026
  • July 30, 2026
  • July 6, 2026
  • April 29, 2026
  • April 8, 2026

Recent SEC filings

Data status

When each part of this page on Regeneron Pharmaceuticals was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Regeneron Pharmaceuticals in brief

What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Regeneron Pharmaceuticals's stock ticker?
Regeneron Pharmaceuticals trades under the ticker REGN on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Regeneron Pharmaceuticals's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Regeneron Pharmaceuticals reported revenue of $16.9B, 18.6% higher than a year earlier, according to its SEC filings.
What is Regeneron Pharmaceuticals's free cash flow?
Regeneron Pharmaceuticals's free-cash-flow margin is 22.6% of revenue over the trailing twelve months, ranking 20 of the 176 biotechnology companies we cover.
What is Regeneron Pharmaceuticals's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Regeneron Pharmaceuticals's free cash flow after stock-based pay gives ~$980 per share in the base case, and ~$760–$1300 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Regeneron Pharmaceuticals's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and Dodge & Cox. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Regeneron Pharmaceuticals buying back stock, and does it pay a dividend?
Regeneron Pharmaceuticals spent $3B on share repurchases over the trailing twelve months, and its diluted share count fell 3.2% over the year.
What is Regeneron Pharmaceuticals's market cap?
On November 2, 2026, Regeneron Pharmaceuticals's market capitalisation was about $103B, with a price-to-earnings ratio of 21.3 and net debt of -$1.7B. Market figures come from third-party market data and may be delayed.
Does Regeneron Pharmaceuticals pay a dividend?
Yes: Regeneron Pharmaceuticals paid $383M in dividends over the trailing twelve months, a dividend yield of 0.38% and a payout ratio of 8.0%.
How much debt does Regeneron Pharmaceuticals have?
Regeneron Pharmaceuticals's debt-to-equity ratio is 5.9%, from its latest balance sheet (9.9% five years earlier). The financial health section below sets out its other solvency checks.
Who are Regeneron Pharmaceuticals's competitors?
In our Biotechnology peer group, the companies closest to Regeneron Pharmaceuticals are Vertex Pharmaceuticals, Biogen, Gilead Sciences, Amgen and Incyte. The side-by-side comparison below sets their revenue, margins and growth against Regeneron Pharmaceuticals's.
Are insiders buying or selling Regeneron Pharmaceuticals stock?
Over the last 12 months, Regeneron Pharmaceuticals's directors and officers reported 0 open-market purchases and 105 sales on Form 4. The insider trading page charts every trade.
When is Regeneron Pharmaceuticals's next earnings date?
Around January 28, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Regeneron Pharmaceuticals announces its own schedule.